Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

No Thumbnail Available
Issue Date
2016
Our author(s)
Tsang, D.
Department
Keywords
Language
English
Publisher
Elsevier
ISSN
0140-6736
1474-547X
eISSN
ISBN
Type
Article
Citation
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., De Bono, J., Cross, W., Jones, R. J., Thalmann, G., Amos, C., Matheson, D., Millman, R., Alzouebi, M., Beesley, S., Birtle, A. J., Brock, S., Cathomas, R., Chakraborti, P., Chowdhury, S., Cook, A., Elliott, T., Gale, J., Gibbs, S., Graham, J. D., Hetherington, J., Hughes, R., Laing, R., Mckinna, F., Mclaren, D. B., O'sullivan, J. M., Parikh, O., Peedell, C., Protheroe, A., Robinson, A. J., Srihari, N., Srinivasan, R., Staffurth, J., Sundar, S., Tolan, S., Tsang, D., Wagstaff, J. & Parmar, M. K. B. 2016. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet, 387, (10024) 1163-1177.
Pubmed ID
URL
Description